Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Down 1.4% – Here’s What Happened

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)’s stock price was down 1.4% during trading on Friday . The company traded as low as $0.60 and last traded at $0.65. Approximately 18,905 shares traded hands during trading, a decline of 79% from the average daily volume of 88,359 shares. The stock had previously closed at $0.66.

Hepion Pharmaceuticals Trading Down 1.4 %

The firm’s 50 day simple moving average is $0.70 and its two-hundred day simple moving average is $0.94. The firm has a market cap of $3.77 million, a price-to-earnings ratio of -0.10 and a beta of 1.81.

Hepion Pharmaceuticals (NASDAQ:HEPA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.68) earnings per share (EPS) for the quarter.

Institutional Trading of Hepion Pharmaceuticals

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC increased its stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 32.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516,000 shares of the company’s stock after purchasing an additional 126,000 shares during the quarter. Armistice Capital LLC owned approximately 9.43% of Hepion Pharmaceuticals worth $526,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.24% of the company’s stock.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.